Amlodipine Besylate/Atenolol

苯磺酸氨氯地平/阿替洛尔

Report date: 2022/06/27 20:00:35

Base Information

Drug NameAmlodipine Besylate/Atenolol
Drug Alias NameAmlodipine Besylate+Atenolol苯磺酸氨氯地平和阿替洛尔Amlodipine Besylate-Atenolol mixt氨氯地平/阿替洛尔阿替洛尔/氨氯地平 +[13] 
ClassificationSmall molecules
Mechanisms of ActionVoltage-gated calcium channel blockers
TargetsVoltage-gated calcium channelAdrenergic receptors
Therapy Area/IndicationsEssential Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes AtenololAmlodipine Besylate
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesChina Resources Double-Crane Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChina Resources Double-Crane Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsEssential Hypertension

Other Information

ATC CodeN/A
Related LinksN/A